Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia
NCT ID: NCT04385056
Last Updated: 2021-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
15 participants
INTERVENTIONAL
2020-12-15
2022-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)
NCT02235844
Expanded Access Study of UC-MSC in DMD Patients
NCT06579352
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia
NCT01360164
The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis
NCT01494480
Neurologic Stem Cell Treatment Study
NCT02795052
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low Dose MSCTC-0010
Participants will receive low-dose cell administration
MSCTC-0010
MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
Medium Dose MSCTC-0010
Participants will receive medium-dose cell administration
MSCTC-0010
MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
High Dose MSCTC-0010
Participants will receive high-dose cell administration
MSCTC-0010
MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MSCTC-0010
MSCTC-0010 is a suspension product for infusion. The active ingredient is the umbilical cord-derived allogeneic mesenchymal stem cells (US-MSCs).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinically diagnosed with Parkinsonism
* All subjects, or their authorized representatives, must be adequately informed and understand the nature and risks of the study and must be able to provide a signature and date in the Informed Consent Form (ICF).
* Clinically diagnosed bradykinesia for at least 3 months prior to baseline visit.
* On stable treatment regimen with L-dopa and other anti-parkinsonian treatment for 4 weeks prior to baseline.
* Women of child-bearing potential must undergo a negative serum pregnancy test at the screening assessment.
* Subjects, or their representatives, must be able to communicate effectively with the study staff.
* Subjects, or their authorized representatives, must certify that they are able and willing to follow all protocol requirements and study restrictions.
Exclusion Criteria
* Subjects who cannot tolerate a venipuncture and/or have adequate venous access.
* Inability to ambulate 100 feet independently with or without an assistive device.
* Subjects who have a history of allergy, hypersensitivity, or intolerance to any medications, components, or excipients of the investigational product or procedures, and which cannot be resolved by the staff conducting the study.
* Subjects with a known diagnosis of Atypical Parkinsonian Syndrome e.g.:
1. Dementia with Lewy Bodies;
2. Progressive Supranuclear Palsy;
3. Corticobasal Degeneration;
4. Multiple System Atrophy;
5. Other Neurodengerative Conditions.
* Head trauma related to the onset of bradykinesia symptoms.
* History of repeated head injury, hydrocephalus, encephalitis, or cerebral tumors.
* Choreoathetosis
* Any documented abnormality in the brain by CT or MRI, which might contribute to the motor function, e.g., stroke, tumor, or other space-occupying lesions, hydrocephalus, or encephalomalacia.
* Known history of serum or plasma progranulin level \< 110.9 ng/mL.
* Disease associated mutation in TDP-34, PGRN, CHMPB2, or VCP genes or any other FTLD Causative genes.
* Intracranial operation, e.g., pallidotomy, thalamotomy, and/or deep brain stiumulation surgery.
* Other known neurodegenerative diseases not underlying the bradykinesia, e.g., Spinocerellar Atropy (SCA), Wilson's Disease, or Amyotrphic Lateral Sclerosis (ALS).
* History of other significant neurological or physciatric disorders including, but not limited to, Alzheimer's disease, Lewy Body Dementia, Prior Disease, stroke, or seizure disorder.
* Psychiatric illness that is unrelated to the Bradykinesia, e.g., severe bipolar or unipolar depression.
* History of neurotoxin exposure.
* History of REM behavior disorder.
* Patients with Hepatocellular Carcinoma (HCC).
* Acute liver failure or episode of hepatic encephalopthy.
* Systolic blood pressure greater than 180 or less than 90 mmHg.
* Diastolic blood pressure greater than 105 or less than 50 mmHg.
* Presence of QTcprolongation or ECG abnormal at screening and judged to be clinically significate by the site investigator.
* Clinically significant cardiovascular disease, e.g., cardiac surgery or myocardial infarction within the last 6 months, unstable angina, congestive heart failure, significant cardaic arrthymia; or cogenitial heart disease.
* Early, symptomatic autonomic dysfunction.
* Any malignancy (other than non-metasticic basal cell carcinoma of the skin) with 5 years of screening.
* Clinically significant lab abnormalities at screening, including creatinine ≥ 2.5 mg/dL, vitam B12 below laboratory normal reference range, or TSH above laboratory normal reference range.
* Current clinically significant hematological, endocrine, cardiovascular, renal, heapatic, gastrointestinal, or neurological disease. For the non-cancerconditions, if the condition has been stable for at least the past year and is judged by the site investigator not to interfere with the patient's participation in the study, the patient may be included.
* A history of alcohol or substance abuse within 1 year prior to screening and deemed to be clinically significant by the site investigator.
* An employee or relative of an employee.
* Subjects who have donated plasma or platelets or had a significant loss of whole blood (480 ml or more) within 30 days.
* Subjects who have received blood or blood products within 30 days prior to screening.
* Treatment with any investigational drugs or device or participation in an investigational drug study within 60 days of screening.
* Women of childbearing potential who are not using at least two forms of medically recognized contraception.
* Female subjects who are pregnant, expecting to become pregnant, or lactating/nursing.
* Any subjects who have a clinically significant abnormal laboratory value.
* Subjects who have been treated with another research product 30 days prior to the screening assessment, or plant to participate in another clinical trial, while in this study. If more than 30 days have passed since participation in another clinical trial, the study staff must ensure that the subject has recovered from any adverse events associated with the research product used.
* Subjects who have a history of any other clinically significant disease or disorder that in the opinion of the Principal Investigator, may place the subject at risk due to participation in the study, or may influence the results of the study.
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IMAC Holdings, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IMAC Regeneration Center
Paducah, Kentucky, United States
Ozzie Smith IMAC Regeneration Center
Chesterfield, Missouri, United States
David Price IMAC Regeneration Center
Brentwood, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMAC-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.